| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Cancer Genetics Unit (M.S.E., J.M.S., R.J.C.-B., K.L.M.), Kolling Institute of Medical Research, Department of Anatomical Pathology (A.J.G., A.C.), Royal North Shore Hospital, and Department of Neurosurgery (R.J.C., N.S.L.), Royal North Shore and North Shore Private Hospitals, Sydney, New South Wales 2065, Australia; University of Sydney (A.J.C., A.C.), and Faculty of Medicine (B.G.R.), Sydney, New South Wales 2006, Australia; Department of Endocrinology (J.V.C.), Waikato Hospital, Waikato 3204, New Zealand; and Department of Neurosurgery (A.J.J.L.), Auckland City Hospital, Auckland 1023, New Zealand
Address all correspondence and requests for reprints to: Marianne S. Elston, M.B. Ch.B., Cancer Genetics Unit, Kolling Institute of Medical Research, Royal North Shore Hospital, St. Leonards, New South Wales 2065, Australia. E-mail: marianne{at}med.usyd.edu.au.
 |
Abstract |
|---|
 Top Abstract IntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
|
Introduction |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
1 cm). The etiology of pituitary tumors is not fully understood but is thought to be a multistep process involving both intrinsic molecular defects and hormonal/growth factor stimulation (1). Aberrant Wnt signaling has been described in many tumor types. There are at least three Wnt pathways, and the Wnt-β-catenin, or canonical, pathway is the best characterized of these. The canonical pathway has been studied most extensively in colon cancer (2) but has also been implicated in the pathogenesis of other human malignancies (see review, Ref. 3). In the canonical pathway, binding of the Wnt ligand to the Frizzled-lipoprotein-related protein receptor complex results in stabilization of β-catenin such that it accumulates in the cytoplasm and translocates into the nucleus to regulate target gene transcription. Secreted Wnt antagonists are involved in regulating the Wnt pathways. These Wnt inhibitors are divided into two main families containing either secreted frizzled-related proteins (sFRPs) or the Dickkopf (DKK) proteins. The sFRP family comprises five sFRPs [sFRP 1–5; sFRP3 is also known as Frizzled B (FRZB)] and Wnt inhibitory factor 1 (WIF1). The sFRPs bind directly to Wnt ligands, thereby preventing their interaction with the Frizzled-lipoprotein-related protein receptor complex and downstream Wnt signaling. Down-regulation of WIF1 and sFRP1-5 gene expression has been reported in a number of tumor types (4, 5, 6, 7, 8), and epigenetic silencing for WIF1 and the sFRP family by CpG island methylation has been demonstrated in several cancers (5, 6, 8, 9, 10, 11, 12, 13, 14, 15). Recent work has shown that reduced expression of Wnt pathway inhibitors may occur in colorectal tumors even if they also contain other downstream Wnt pathway mutations, suggesting that loss of these inhibitors may have an additional role in tumor growth (12).
Data on the Wnt pathways in pituitary tumors is limited. Immunohistochemical staining of pituitary tumors for β-catenin has been reported, but results have been conflicting with respect to the frequency of cytoplasmic and nuclear protein accumulation (16, 17, 18, 19, 20). Nuclear accumulation of β-catenin has been reported to be present in 57% of pituitary tumors (17); however, an independent study demonstrated nuclear staining in only 1% of tumors (18). Mutations in the genes encoding β-catenin, AXIN1, adenomatous polyposis coli, and glycogen synthase kinase 3β have been assessed but appear to be infrequent even in those pituitary tumors reported to show nuclear β-catenin accumulation (18, 21, 22). The only report of a Wnt inhibitor in pituitary tumors comes from a microarray study where elevated sFRP1 mRNA expression in NFAs was identified (23).
The aim of the current study was to find genes potentially involved in pituitary tumor pathogenesis using microarray analysis. We report the reduced expression of WIF1 and three other sFRPs common to both nonfunctioning and functioning pituitary tumors. Further confirmation by real-time quantitative PCR (qPCR) and immunohistochemistry suggests that aberrant Wnt pathway activity may be associated with pituitary tumorigenesis. The downstream target of activated Wnt pathway signaling, cyclin D1, was also found to be up-regulated in pituitary tumors but not normal pituitary. Putative WIF1 tumor suppressor function was investigated, and restoration of WIF1 in rat pituitary GH3 cells resulted in reduced cell proliferation.
|
Materials and Methods |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Tumors were classified according to functional subtype based on clinical and hormonal evaluation. Additional information was provided by histological assessment and immunohistochemical staining for all anterior pituitary hormones. All tumors were sporadic, and there were no carcinomas.
Microarray studies were performed on a core group of 20 pituitary tumors and three normal controls. The qPCR was performed on an expanded group of 42 patients that included all 20 tumors used for the microarray with an additional 22 tumors and a total of five normal controls. All samples used for qPCR also had methylation assessment of the WIF1 promoter except one tumor in which there was insufficient DNA. Forty-one tumors were used for immunohistochemistry for WIF1 with an additional 29 tumors included for β-catenin immunohistochemistry to obtain representative numbers for each tumor subtype. Twenty-seven of the samples from the qPCR were included in the immunohistochemistry and so had matched expression, methylation, and immunohistochemical data. Thirteen normal pituitary controls (comprising normal pituitary gland away from resected adenomas) were included in these immunohistochemical studies. The patient clinical characteristics are shown in Table 1
.
|
Tumor subtype confirmation and exclusion of normal pituitary contamination
RT-PCR for pituitary transcription factor-1 (Pit-1) and proopiomelanocortin (POMC) was performed on all tumors and controls included in microarray and qPCR analyses, both to confirm subtype and to exclude significant normal anterior pituitary contamination as previously described (24). The primer sequences used for POMC were 5'-AGGACCTCACCACGGAAAG-3' (forward) and 5'-CATGGAGTAGGAGCGCTTG-3' (reverse). The primers for Pit-1 were 5'-GGAAACCAGCCATCAACCTA-3' (forward) and 5'-ACTTTTCCGCCTGAGTTCCT-3' (reverse).
Microarray
RNA labeling, hybridization to the Affymetrix GeneChip Human Genome U133 plus 2.0 Arrays and scanning was performed by the Clive and Vera Ramaciotti Centre for Gene Function Analysis (University of New South Wales, Sydney, Australia).
Preprocessing of the CEL file and normalization were performed using Robust Multichip Average (RMA) using R statistical software version 2.3.1 libraries contained in Bioconductor (http://www.bioconductor.org/). The AffylmGUI analysis suite (Bioconductor), which uses a moderated t statistic (25), was applied to the normalized data set using the Benjamini-Hochberg correction, and differentially expressed genes were identified using an M-value of less than or equal to –1 or greater than or equal to 1 (log 2-fold change) and a B-statistic (log-odds expression) of greater than or equal to 2. Four separate analyses were performed, all tumors vs. normal pituitary, NFA vs. normal, GH-secreting (GH-S) vs. normal and ACTH-secreting (ACTH-S) vs. normal.
qPCR
Total RNA from each tumor and normal tissue was reverse-transcribed into cDNA using random hexamers and the Superscript III first-strand synthesis system (Invitrogen). qPCR was performed on a Corbett Rotor-Gene 3000 (Corbett Research, Mortlake, New South Wales, Australia) using gene-specific TaqMan Gene Expression Assays and TaqMan Universal PCR Master Mix (Applied Biosystems, Foster City, CA). Each PCR was performed as a duplex reaction with the gene-specific FAM-TAMRA-labeled TaqMan probe and a VIC-labeled TaqMan probe and ribosomal 18S RNA as the internal control for normalization (Applied Biosystems). All samples were run in triplicate and repeated a minimum of two times. Analysis of the qPCR results was performed using the relative expression software tool (REST 2005) (26) with relative expression ratios calculated based on the PCR efficiency and crossing points.
DNA extraction
DNA was extracted from fresh-frozen pituitary tumor tissue (15–50 mg) and one normal pituitary gland using TRIzol reagent according to the manufacturer’s protocol (Invitrogen). DNA concentration and purity was measured by UV absorbance at 260/280nm (Nanodrop ND-1000; Biolab). Five additional normal pituitaries were extracted to use as comparison with the tumors in methylation studies.
Bisulfite treatment and genomic methylation sequencing
Bisulfite treatment of DNA was performed using the Methyl Easy DNA Bisulfite Modification Kit according to the manufacturer’s protocol (Human Genetic Signatures Pty. Ltd., Sydney, Australia). Briefly, 1 µg DNA was treated with 3 M NaOH, followed by overnight bisulfite treatment (15 h). Two overlapping PCR were performed to amplify a 661-bp area (–543 to +118, relative to the translation start site) of the WIF1 promoter containing 64 CpG dinucleotides. The primers used were as previously reported: forward 5'-TAGGGGTTTTTGAGTGTTT-3' and reverse 5'-ACCTAAATACCAAAAAACCTAC-3' (5); forward 5'-GTAGGTTTTTTGGTATTTAGG-3' and reverse 5'-TCCATAAATACAAACTCTCCTC-3' (14). CpGenome universal methylated and unmethylated controls were included with each reaction (Chemicon International Inc., Temecula, CA). Sequencing was performed by Sydney University Prince Alfred Macromolecular Analysis Centre (SUPAMAC) using the ABI PRISM 3700 platform (Applied Biosystems).
Immunohistochemistry
Immunohistochemistry for β-catenin (n = 70), WIF1 (n = 41), and cyclin D1 (n = 26) was performed on formalin-fixed paraffin-embedded tissue using a mouse monoclonal antibody for β-catenin (17C2; Novocastra, Newcastle-upon-Tyne, UK) and WIF1 (133015; R&D Systems, Inc., Minneapolis, MN) and a rabbit monoclonal antibody for cyclin D1 (Clone SP4, catalog item RM-9104-S; Neomarkers Inc., Fremont CA). Thirteen normal pituitary controls were included in each analysis. Representative blocks from each tumor were sectioned at 4 µm onto positively charged slides (SuperFrost Plus; Menzel-Glaser, Braunschweig, Germany). Slides were then stained using the Vision Biosystems BondMax Autostainer (Vision Biosystems, Mount Waverley, Victoria, Australia) according to the manufacturer’s protocol. Briefly, slides were dewaxed in Bond Dewax solution (AR9222; Vision Biosystems) and hydrated in Bond Wash solution (AR9590; Vision Biosystems). Antigen retrieval was performed at an alkaline pH using Epitope Retrieval 2 solution (AR9640; Vision Biosystems) for 20 min at 100 C. Slides were then incubated with the primary antibody at a concentration of 1:100 (β-catenin), 1:50 (WIF1), or 1:25 (cyclin D1) for 30 min at room temperature. Antibody detection was performed using the biotin-free Bond Polymer Defined Detection System (DS9713; Vision Biosystems). Slides were counterstained with hematoxylin. External positive and negative controls were examined with each batch of stains.
Staining for β-catenin was evaluated as previously outlined (18). Briefly, immunostaining results were scored as 0 (negative), 1+ (weak), 2+ (moderate), and 3+ (strong) for each of the locations: cytoplasmic membrane (CM), cytoplasm (C), and nuclear (N). For WIF1, cytoplasmic staining was evaluated based on the scoring system above. For cyclin D1, a score of 0 was assigned to tumors that were completely negative, 1+ indicated occasional positive cells (less than 5% of total tumor cells), 2+ indicated moderate staining of tumor (5–30% of tumor cells positive), and a score of 3+ indicated diffuse strong positive staining (defined as more than 30% of tumor cells positive, but usually all tumor cells showing diffuse positive staining). For the purposes of binary analysis, scores of 0 and 1+ can be considered negative and scores of 2+ and 3+ positive. The pituitaries were evaluated by a single observer (A.J.G.) in conjunction with a hematoxylin- and eosin-stained slide. The observer was blinded as to other information.
In vitro studies
The rat pituitary GH3 cell line was a generous gift from C. Chen (Prince Henry’s Institute of Medical Research, Melbourne, Australia). Cells were grown in 45% DMEM, 45% Ham’s F12, with 10% fetal bovine serum and cultured at 37 C with 5% CO2.
RNA was extracted from cells to assess endogenous WIF1 levels using the Trizol method as above.
Whole-cell lysates were obtained by harvesting the cell cultures and lysing in SDS protein lysis buffer and denatured (95 C, 10 min) before electrophoresis on 8% SDS-polyacrylamide gels. For Western blot analysis, separated proteins were transferred to Hybond ECL nitrocellulose membranes (GE Healthcare, Piscataway, NJ) and probed with WIF1 (133015; R&D Systems) at 1:1600 and 
-tubulin (DM1A; Sigma Chemical Co., St. Louis, MO) at 1:10,000. The Amersham ECL Plus Western Blotting Detection Reagents (GE Healthcare) were used for protein detection.
Full-length human WIF1 cDNA was cloned into pcDNA3 and pcDNA4 T/O. Cells were transfected with either WIF1-containing pcDNA3 or pcDNA3 empty vector (EV) using Effectene Transfection Reagent according to the manufacturer’s instructions (QIAGEN, Valencia, CA).
Cell proliferation studies were performed by plating 1 x 105 cells per well in a 96-well plate 24 h before transfection, and proliferation was assessed using CellTiter 96 Aqueous MTS Reagent (Promega, Madison, WI). Experiments were performed in at least triplicate and repeated three times.
Colony formation assay was performed by plating EV- or WIF1-transfected cells in soft agar at 5,000 and 10,000 cells per well in six-well plates, using G418 400 µg/ml to select transfected cells. Plates were stained with 0.5% crystal violet 3 wk after transfection and colonies counted.
Statistics
Generalized linear modeling using the binomial distribution with probit link was used to assess the relationship between methylation status and tumor type, and methylation status vs. mRNA expression. ANOVA followed by post-estimation matrix testing was used to assess the significance of mRNA expression for the tumors compared with normal pituitary. Logistic regression was used to assess immunohistochemistry results (absent/weak vs. moderate/strong staining). A P value below 0.05 was considered significant.
|
Results |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Microarray
A total of 1253 genes were differentially expressed in all pituitary tumors when compared with the normal controls (supplemental Tables 1–4, published as supplemental data on The Endocrine Society’s Journals Online web site at http://endo.endojournals.org). After separating the tumors into the clinical subtypes (NFAs, GH-S, ACTH-S), the NFAs showed more differentially expressed genes compared with the functional tumors (876 vs. 377, respectively) consistent with a previous study (27).
One of the most differentially expressed genes (both in terms of fold change and significance) in the pituitary tumors compared with normal pituitary was WIF1 (Table 2). This gene was consistently down-regulated across all three tumor subtypes: NFAs, GH-S, and ACTH-S (97-, 91-, and 91-fold, respectively). Because WIF1 is a member of the sFRP family of Wnt inhibitors, we reviewed the list of differentially expressed genes to see whether the other five sFRPs were differentially expressed. Three other members of the sFRP family, sFRP2, FRZB, and sFRP4, were also significantly down-regulated when comparing the total group of pituitary tumors to the normal controls, and sFRP1 was also differentially expressed (increased 2.5-fold), although this was not significant (B-statistic, –6) (Table 2).
|
). After separating the tumors into their clinical subtypes, WIF1 mRNA expression was significantly underexpressed in all groups when compared with the normal pituitary controls (down 3468-fold in the NFAs, P = 0.001; down 867-fold in the GH-S, P = 0.011; down 1734-fold in the ACTH-S, P = 0.034). Both sFRP2 and sFRP4 were also significantly reduced in pituitary tumors when compared with normal controls (P = 0.002 and 0.013, respectively) (Fig. 1). The mRNA expression of sFRP2 was significantly underexpressed in the NFAs (down 339-fold, P = 0.001) and ACTH-S (down 47-fold, P = 0.034) but did not reach statistical significance in the GH-S tumors (down 268-fold, P = 0.059). SFRP4 mRNA expression was significantly down-regulated in the NFAs (down 13-fold, P = 0.004), GH-S (down 9-fold, P = 0.008), and ACTH-S (down 59-fold, P = 0.034). FRZB mRNA expression was down 4-fold compared with the controls; however, this decrease did not reach statistical significance (P = 0.073). Because sFRP1 has previously been reported to be elevated in NFAs (23), qPCR for sFRP1 was also performed. sFRP1 mRNA expression showed marked variation in the NFAs (Fig. 1A) with a subset demonstrating elevated mRNA expression compared with the controls. However, when analyzed as a group, sFRP1 mRNA expression in the NFAs did not significantly differ from the controls (P = 0.230) but was significantly higher when compared with the other tumors (P = 0.006). The mRNA expression levels of the remaining sFRP family member, sFRP5, was also assessed; however, this gene was not significantly different in the tumors compared with the controls (P = 0.707) (Fig. 1A). The downstream Wnt target gene cyclin D1 was also assessed by qPCR. The mRNA expression levels were significantly elevated in all pituitary tumors (n = 42) compared with normal pituitary controls (n = 5) (P = 0.0112). However, when the tumors are categorized into functioning and nonfunctioning subtypes, only the NFAs significantly differed from normal pituitary controls (P = 0.0022). No significant differences were measured for the clinically functioning subtypes when compared with the normal pituitary controls (P = 0.29 and P = 0.65 for the GH-S and ACTH-S adenomas, respectively) (Fig. 1B).
|
). Methylation was present in 36 of 41 tumors (88%), significantly higher than the controls (P = 0.001). The 31 NFAs showed a higher percentage of methylation compared with the 10 functioning tumors (P = 0.002). Five tumors had no methylation (all three ACTH-S and two of the seven GH-S). Although heterogeneous methylation was typically observed in the tumors, an extensive area between –438 and –380 bp, relative to the translational start site, was consistently unmethylated (Fig. 2).
|
).). When compared with the normal pituitary WIF1, cytoplasmic staining was significantly reduced in 31 of 41 (76%) pituitary tumors (P < 0.001) (Fig. 3B). Of the 10 pituitary tumors that did not show loss of WIF1 staining, seven were functional [five GH-S (Fig. 3C) and two ACTH-S].
|
|
). No nuclear accumulation of β-catenin was present in any tumor or normal tissue. Lower values of WIF1 and sFRP5 mRNA expression were associated with higher levels of cytoplasmic β-catenin staining, but these did not reach statistical significance (P = 0.058 and P = 0.053, respectively). Cytoplasmic staining did not vary according to tumor type (P = 0.704) (Fig. 3, D–F). Cytoplasmic membrane staining did not correlate with the mRNA expression of WIF1 and sFRPs in the tumors. The NFAs demonstrated higher cell membrane β-catenin staining than the other tumor types (P = 0.036) (Fig. 3E).
Cyclin D1.
Normal pituitary tissue demonstrated weak or absent nuclear staining for cyclin D1. In contrast, in 73% (n = 26) of pituitary tumors, moderate (2+) to strong (3+) staining was observed. Similar to the findings for the mRNA expression, the NFAs showed increased staining compared with the functioning tumors (P = 0.01) (Fig. 3, H–I). Immunohistochemistry strongly correlated with qPCR results (P = 0.002).
In vitro studies
GH3 WIF1 expression.
The rat pituitary GH3 cell line was previously untested for endogenous levels of WIF1. To assess its suitability as a functional model, WIF1 mRNA levels were measured using qPCR. WIF1 expression was significantly reduced (22-fold) when compared with normal human pituitary (P < 0.001).
Cell proliferation studies.
Because we found that WIF1 was underexpressed in the GH3 pituitary cell line, we transfected WIF1 into these cells to determine whether loss of expression of WIF1 contributes to pituitary tumor cell proliferation. Three days after transfection, we found significantly reduced cell proliferation in the cells transfected with WIF1 compared with the cells transfected with the EV using MTS assay (P = 0.015) (Fig. 4A). Reduced colony formation was also seen in WIF1-transfected cells compared with EV (P = 0.039) at 3 wk after transfection (Fig. 4B).
|
|
Discussion |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Reduced mRNA expression of WIF1 is common to all four subtypes examined (NFA, GH-S, ACTH-S, and TSH-S). The otherwise diverse biological behavior of these clinical subtypes of pituitary tumors suggests that reduced WIF1 expression may be a common and early pathogenetic hallmark. Decreased expression of WIF1 has been identified in 73% of colorectal adenomas (10) and therefore also appears to occur early in colorectal tumor development. Interestingly, the protein expression of WIF1 was more variably affected with loss of expression predominantly seen in the NFAs despite similar levels of mRNA expression. The reason for this differential expression between subtypes is currently unclear.
By restoring WIF1 levels in the rat pituitary GH3 cell line, we demonstrated reduced cell growth and inhibited colony formation. Our data support previous work that identifies WIF1 as a potential tumor suppressor gene (7, 28). In other studies, by restoring WIF1 expression to esophageal and colorectal cancer cell lines, a reduction in growth rate and colony numbers was also observed (10) and apoptosis was increased (13). Overexpression of the sFRPs has been demonstrated to result in decreased colony formation and increased rates of apoptosis in colorectal cell lines (12), and there is increasing evidence for the role of these genes as tumor suppressors in other tissues (29, 30, 31, 32). However, although most studies have supported the role of the sFRP family as having tumor suppressor effects, a few studies suggest that in certain tissues and contexts they may have the opposite effect, i.e. growth promotion (reviewed in Ref. 33), which necessitates further investigation into these factors in more tissue types and pathological conditions.
Approximately half of all human genes contain a CpG island in their promoters (34), and methylation of these CpG dinucleotides can lead to gene silencing (35). WIF1 contains a CpG island within its promoter (14), and low expression due to promoter methylation has been demonstrated in a number of human tumors (5, 6, 9, 10, 14, 15). In addition, treatment of tumor cell lines with demethylating agents has been shown to restore expression of WIF1, suggesting that promoter methylation is the likely mechanism of the reduced gene expression (6, 10, 11, 14). Our data show heterogeneous methylation of the WIF1 promoter in 88% of tumors examined. We identified a hypomethylated region in our study, –438 to –380, which contains two putative Sp1 binding sites (GGGCGG) on sequence analysis. Sp1 binding sites have previously been demonstrated to be more resistant to methylation (36), and this hypomethylated region is consistent with the findings of Ai et al. (6). The clinically functioning tumors had significantly lower rates of methylation than the NFAs, and five clinically functioning tumors (including the three ACTH-S) showed no WIF1 promoter methylation. Increased methylation was not associated with reduced WIF1 mRNA expression levels. Our data suggest that methylation may contribute to the reduced WIF1 expression in NFAs but that there may be other mechanisms involved in the functioning pituitary tumors.
β-Catenin is the central mediator of the canonical Wnt signaling pathway, and reports on the presence of abnormal nuclear β-catenin accumulation in pituitary tumors have been conflicting (16, 17, 18, 19, 20). In this study, we observed no abnormal nuclear β-catenin accumulation in 70 tumors, which is in agreement with the reports suggesting that nuclear accumulation of β-catenin is uncommon in pituitary tumors (16, 18, 19, 20). Furthermore, we have shown heterogeneous β-catenin staining within normal pituitary, which has not been previously reported. In the 27 tumors with combined mRNA expression data for WIF1 and sFRP1–5 and immunohistochemistry for β-catenin available, association between cytoplasmic β-catenin staining and WIF1 and sFRP5 mRNA expression levels was of borderline significance. One possible explanation for the lack of nuclear β-catenin and only weak cytoplasmic staining in the NFAs is the elevation in sFRP1 seen in a subset of these tumors because sFRP1 has been reported to be a target of the hedgehog pathway, which can inhibit Wnt signaling (37, 38). However, even in tumors with reduced expression of all six inhibitors compared with normal pituitary, there was no nuclear β-catenin staining. We have not assessed the expression of the DKK family of Wnt inhibitors in pituitary tumors using qPCR. From our microarray data, only DKK2 was differentially expressed, and this was down-regulated 2.6-fold, suggesting that these family members are unlikely to be contributing to the lack of nuclear β-catenin accumulation. However, we have demonstrated increased expression of the Wnt target gene, cyclin D1, at both the mRNA and protein levels in the NFAs, which is supportive of activation of the canonical Wnt pathway in this pituitary tumor subtype. Larger numbers of functioning tumors are needed to elucidate whether a different pathway is operational in the functioning subtypes. Further work into this pathway in pituitary tumorigenesis is required.
In conclusion, pituitary tumors demonstrate down-regulation of WIF1 mRNA, which is common to all pituitary tumor subtypes with a reduction in WIF1 protein levels predominantly limited to the NFAs. In addition, the other sFRP family members are affected in a more variable manner, suggesting that the Wnt pathways are important in pituitary tumorigenesis. Our in vitro studies show that WIF1 acts to slow pituitary cell growth, and these data are consistent with our clinical data in that loss of WIF1 is associated with pituitary tumorigenesis. Our data suggest that WIF1 mRNA down-regulation in pituitary tumors is an early event because it is reduced in all tumor subtypes and that later genetic events may explain the differences in tumor behavior seen in the different pituitary tumor subtypes.
|
Acknowledgments |
|---|
|
Footnotes |
|---|
Abbreviations: ACTH-S, ACTH-secreting; DKK, Dickkopf; EV, empty vector; GH-S, GH-secreting; NFA, nonfunctioning adenoma; qPCR, quantitative PCR; sFRP, secreted frizzled-related protein; WIF1, Wnt inhibitory factor-1.
This work was supported by a project grant-in-aid from the Waikato Medical Research Foundation. M.S.E. was supported by a National Health and Medical Research Council medical postgraduate research scholarship and New South Wales Cancer Institute Research Scholars Award.
Disclosure Statement: All authors have nothing to declare.
Received May 2, 2007.
Accepted for publication December 4, 2007.
|
References |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
-, β-, and 
-catenin expression in normal and neoplastic human pituitary tissues. Endocr Pathol 12:125–136[CrossRef][Medline]-, β-, and -catenins, and p120 (cell adhesion molecules) in prolactinoma behavior. Mod Pathol 15:1357–1365[CrossRef][Medline]This article has been cited by other articles:
 |
|
 |
|
  M. S. Elston, A. J. Gill, J. V. Conaglen, A. Clarkson, R. J. Cook, N. S. Little, B. G. Robinson, R. J. Clifton-Bligh, and K. L. McDonald Nuclear Accumulation of E-Cadherin Correlates with Loss of Cytoplasmic Membrane Staining and Invasion in Pituitary Adenomas J. Clin. Endocrinol. Metab., April 1, 2009; 94(4): 1436 - 1442. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Tang, A. R. Simoneau, W.-x. Liao, G. Yi, C. Hope, F. Liu, S. Li, J. Xie, R. F. Holcombe, F. A. Jurnak, et al. WIF1, a Wnt pathway inhibitor, regulates SKP2 and c-myc expression leading to G1 arrest and growth inhibition of human invasive urinary bladder cancer cells Mol. Cancer Ther., February 1, 2009; 8(2): 458 - 468. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. A. Payne, S. Maleki, M. Messina, M. G. O'Sullivan, G. Stone, N. R. Hall, J. F. Parkinson, H. R. Wheeler, R. J. Cook, M. T. Biggs, et al. Loss of prostaglandin D2 synthase: a key molecular event in the transition of a low-grade astrocytoma to an anaplastic astrocytoma Mol. Cancer Ther., October 1, 2008; 7(10): 3420 - 3428. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
